|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
25,920,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with gastrointestinal, or GI, diseases. Co.'s program, MET642, targets the farnesoid X receptor, or FXR, which is central to modulating GI and liver diseases. Co. is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis. Co. is also developing small molecule inhibitors of hydroxysteroid dehydrogenase 17b13, or HSD17ss13, for the treatment of NASH. HSD17ss13 is a genetically validated target for liver disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
2,510,570 |
Total Buy Value |
$0 |
$0 |
$0 |
$936,096 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
11 |
Total Shares Sold |
0 |
0 |
0 |
487,659 |
Total Sell Value |
$0 |
$0 |
$0 |
$201,597 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Burow Kristina |
Director |
|
2020-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,710,503 |
138,734 |
|
- |
|
Arch Venture Partners Viii, L.p. |
10% Owner |
|
2020-09-18 |
4 |
B |
$13.00 |
$2,990,000 |
I/I |
230,000 |
158,734 |
1.5 |
- |
|
Arch Venture Partners Viii, L.p. |
10% Owner |
|
2020-09-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,710,503 |
138,734 |
|
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2020-09-18 |
4 |
B |
$13.00 |
$499,993 |
D/D |
38,461 |
1,307,256 |
2.45 |
- |
|
Alexandria Venture Investments, Llc |
10% Owner |
|
2020-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,268,795 |
1,268,795 |
|
- |
|
Heyman Richard A. |
Director |
|
2020-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,177 |
|
- |
|
Millican Trisha |
Chief Financial OfficerOfficer |
|
2020-09-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
57,445 |
|
- |
|
Millican Trisha |
Chief Financial OfficerOfficer |
|
2020-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
41,033 |
|
- |
|
Evans Ronald M |
Director |
|
2020-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
424,693 |
|
- |
|
84 Records found
|
|
Page 4 of 4 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|